Limits...
Podocytes express IL-6 and lipocalin 2/ neutrophil gelatinase-associated lipocalin in lipopolysaccharide-induced acute glomerular injury.

Lee SJ, Borsting E, Declèves AE, Singh P, Cunard R - Nephron Exp. Nephrol. (2012)

Bottom Line: Plasma levels of interleukin (IL)-6 predict the development of AKI and are associated with higher mortality in ICU patients with AKI.Surprisingly, in direct response to exogenous IL-6, podocytes produce lipocalin-2/neutrophil gelatinase-associated lipocalin (Lcn2/Ngal).The glomerulus is involved in septic AKI, and we demonstrate that podocytes secrete key mediators of AKI including IL-6 and Lcn2/Ngal.

View Article: PubMed Central - PubMed

Affiliation: Research Service and Division of Nephrology-Hypertension, Veterans Affairs San Diego Healthcare System, Veterans Medical Research Foundation, San Diego, CA 92161, USA.

Show MeSH

Related in: MedlinePlus

LPS augments podocyte expression and secretion of Lcn2/Ngal. Fully differentiated transformed podocytes were treated with LPS (10 ng/ml) for various time points and Lcn2/Ngal mRNA (a)and supernatant protein expression (b) were evaluated. C = Control. c Western blotting was performed on concentrated culture supernatants (23 μg protein/lane) of podocytes treated with graded concentrations of LPS. Primary podocytes derived from C57BL/6 mice were treated with 10 ng/ml LPS and Lcn2/Ngal mRNA (d) and supernatant protein expression (e) was assessed at 24 h. f Primary podocytes were grown on coverslips and stained with classic podocyte markers synaptopodin and WT-1.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4012854&req=5

Figure 4: LPS augments podocyte expression and secretion of Lcn2/Ngal. Fully differentiated transformed podocytes were treated with LPS (10 ng/ml) for various time points and Lcn2/Ngal mRNA (a)and supernatant protein expression (b) were evaluated. C = Control. c Western blotting was performed on concentrated culture supernatants (23 μg protein/lane) of podocytes treated with graded concentrations of LPS. Primary podocytes derived from C57BL/6 mice were treated with 10 ng/ml LPS and Lcn2/Ngal mRNA (d) and supernatant protein expression (e) was assessed at 24 h. f Primary podocytes were grown on coverslips and stained with classic podocyte markers synaptopodin and WT-1.

Mentions: To investigate whether LPS had similar effects on podocyte secretion of Lcn2/Ngal, we treated fully differentiated podocytes with LPS. LPS rapidly and potently stimulated Lcn2/Ngal mRNA production in podocytes to levels nearly 20-fold greater than treatment with exogenous IL-6 (fig. 4a). In contrast to the burst of IL-6 mRNA expression (which was dramatically reduced by 4 h) observed after LPS exposure, Lcn2/Ngal mRNA expression increased with LPS treatment in a time-dependent manner. By 24 h, there was a 1,100-fold increase in Lcn2/Ngal mRNA expression with supernatant concentrations of Lcn2/Ngal of 29,370 pg/ml. Western blotting performed on culture supernatants confirmed these findings (fig. 4c).


Podocytes express IL-6 and lipocalin 2/ neutrophil gelatinase-associated lipocalin in lipopolysaccharide-induced acute glomerular injury.

Lee SJ, Borsting E, Declèves AE, Singh P, Cunard R - Nephron Exp. Nephrol. (2012)

LPS augments podocyte expression and secretion of Lcn2/Ngal. Fully differentiated transformed podocytes were treated with LPS (10 ng/ml) for various time points and Lcn2/Ngal mRNA (a)and supernatant protein expression (b) were evaluated. C = Control. c Western blotting was performed on concentrated culture supernatants (23 μg protein/lane) of podocytes treated with graded concentrations of LPS. Primary podocytes derived from C57BL/6 mice were treated with 10 ng/ml LPS and Lcn2/Ngal mRNA (d) and supernatant protein expression (e) was assessed at 24 h. f Primary podocytes were grown on coverslips and stained with classic podocyte markers synaptopodin and WT-1.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4012854&req=5

Figure 4: LPS augments podocyte expression and secretion of Lcn2/Ngal. Fully differentiated transformed podocytes were treated with LPS (10 ng/ml) for various time points and Lcn2/Ngal mRNA (a)and supernatant protein expression (b) were evaluated. C = Control. c Western blotting was performed on concentrated culture supernatants (23 μg protein/lane) of podocytes treated with graded concentrations of LPS. Primary podocytes derived from C57BL/6 mice were treated with 10 ng/ml LPS and Lcn2/Ngal mRNA (d) and supernatant protein expression (e) was assessed at 24 h. f Primary podocytes were grown on coverslips and stained with classic podocyte markers synaptopodin and WT-1.
Mentions: To investigate whether LPS had similar effects on podocyte secretion of Lcn2/Ngal, we treated fully differentiated podocytes with LPS. LPS rapidly and potently stimulated Lcn2/Ngal mRNA production in podocytes to levels nearly 20-fold greater than treatment with exogenous IL-6 (fig. 4a). In contrast to the burst of IL-6 mRNA expression (which was dramatically reduced by 4 h) observed after LPS exposure, Lcn2/Ngal mRNA expression increased with LPS treatment in a time-dependent manner. By 24 h, there was a 1,100-fold increase in Lcn2/Ngal mRNA expression with supernatant concentrations of Lcn2/Ngal of 29,370 pg/ml. Western blotting performed on culture supernatants confirmed these findings (fig. 4c).

Bottom Line: Plasma levels of interleukin (IL)-6 predict the development of AKI and are associated with higher mortality in ICU patients with AKI.Surprisingly, in direct response to exogenous IL-6, podocytes produce lipocalin-2/neutrophil gelatinase-associated lipocalin (Lcn2/Ngal).The glomerulus is involved in septic AKI, and we demonstrate that podocytes secrete key mediators of AKI including IL-6 and Lcn2/Ngal.

View Article: PubMed Central - PubMed

Affiliation: Research Service and Division of Nephrology-Hypertension, Veterans Affairs San Diego Healthcare System, Veterans Medical Research Foundation, San Diego, CA 92161, USA.

Show MeSH
Related in: MedlinePlus